Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
No Study Results Posted
Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML)
This study has been completed.
Study NCT00064584 Information provided by Millennium Pharmaceuticals, Inc.
First Received on July 9, 2003. Last Updated on March 23, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Acute Myelogenous Leukemia
Additional conditions recognized in this trial
Leukemia, Myeloid, Acute
More general conditions related to this trial
Bone Marrow Diseases
Neoplasms by Histologic Type
Interventions listed in this trial
Sponsors listed in this trial
Millennium Pharmaceuticals, Inc.
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers